参考文献/References:
1 Alves G, Forsaa EB, Pedersen KF, et al. Epidemiology of Parkinson's disease. J Neurol, 2008,255(Suppl 5):18-32.
2 Braak H, Del T K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 2003,24(2):197-211.
3 Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease.. Mov Disord, 2009,24(11):1641-1649.
4 O'Callaghan C, Shine JM, Lewis SJ, et al. Neuropsychiatric symptoms in Parkinson's disease: fronto-striatal atrophy contributions.. Parkinsonism Relat Disord, 2014,20(8):867-872.
5 Aarsland D, Pahlhagen S, Ballard CG, et al. Depression in Parkinson disease--epidemiology, mechanisms and management.. Nat Rev Neurol, 2012,8(1):35-47.
6 Claassen DO, Josephs KA, Ahlskog J E, et al. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century.. Neurology, 2010,75(6):494-499.
7 Bonnet AM, Jutras MF, Czernecki V, et al. Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects. Parkinsons Dis, 2012,2012:198316.
8 Kostic VS, Pekmezovic T, Tomic A, et al. Suicide and suicidal ideation in Parkinson's disease. J Neurol Sci, 2010,289(1-2):40-43.
9 Storch A, Schneider C B, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology, 2013,80(9):800-809.
10 van Mierlo TJ, Chung C, Foncke E M, et al. Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume. Mov Disord, 2015,30(2):245-252.
11 Remy P, Doder M, Lees A, et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.. Brain, 2005,128(Pt 6):1314-1322.
12 Vriend C, Raijmakers P, Veltman DJ, et al. Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus.. J Neurol Neurosurg Psychiatry, 2014,85(2):159-164.
13 Politis M, Wu K, Loane C, et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis, 2010,40(1):216-221.
14 Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial.. Am J Psychiatry, 2011,168(10):1066-1074.
15 Hanganu A, Degroot C, Monchi O, et al. Influence of depressive symptoms on dopaminergic treatment of Parkinson's disease. Front Neurol, 2014,5:188.
16 Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol, 2010,9(6):573-580.
17 Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression..Neurology, 2009,72(10):886-892.
18 Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology, 2012,78(16):1229-1236.
19 Hewett K, Gee M D, Krishen A, et al. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol, 2010,24(8):1209-1216.
20 Liu J, Dong J, Wang L, et al. Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. PLoS One, 2013,8(10):e76651.
21 Pal E, Nagy F, Aschermann Z, et al. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. Mov Disord, 2010,25(14):2311-2317.
22 Jones JD, Butterfield LC, Song W, et al. Anxiety and Depression Are Better Correlates of Parkinson's Disease Quality of Life Than Apathy. J Neuropsychiatry Clin Neurosci, 2014. PMID: 25162776
23 Rutten S, Ghielen I, Vriend C, et al. Anxiety in Parkinson's disease: Symptom dimensions and overlap with depression and autonomic failure. Parkinsonism Relat Disord, 2015,21(3):189-193.
24 Gultekin BK, Ozdilek B, Bestepe EE. Social phobia in Parkinson's disease: Prevalence and risk factors. Neuropsychiatr Dis Treat, 2014,10:829-834.
25 Leentjens AF, Dujardin K, Marsh L, et al. Symptomatology and markers of anxiety disorders in Parkinson's disease: a cross-sectional study. Mov Disord, 2011,26(3):484-492.
26 Leentjens AF, Dujardin K, Marsh L, et al. Anxiety and motor fluctuations in Parkinson's disease: a cross-sectional observational study. Parkinsonism Relat Disord, 2012,18(10):1084-1088.
27 Ehgoetz MK, Ellard CG, Almeida QJ. Does anxiety cause freezing of gait in Parkinson's disease? PLoS One, 2014,9(9):e106561.
28 Prediger RD, Matheus FC, Schwarzbold ML, et al. Anxiety in Parkinson's disease: a critical review of experimental and clinical studies. Neuropharmacology, 2012,62(1):115-124.
29 Armento ME, Stanley MA, Marsh L, et al. Cognitive behavioral therapy for depression and anxiety in Parkinson's disease: a clinical review. J Parkinsons Dis, 2012,2(2):135-151.
30 Yang S, Sajatovic M, Walter BL. Psychosocial interventions for depression and anxiety in Parkinson's disease. J Geriatr Psychiatry Neurol, 2012,25(2):113-121.
31 Marino L, Friedman JH. Letter to the editor: successful use of electroconvulsive therapy for refractory anxiety in Parkinson's disease. Int J Neurosci, 2013,123(1):70-71.
32 Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci, 2010,289(1-2):12-17.
33 Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-Year Population-Based Study of Psychosis in Parkinson Disease. Arch Neurol, 2010,67(8):996-1001.
34 Goldman JG, Stebbins GT, Dinh V, et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations.. Brain, 2014,137(Pt 3):849-859.
35 Ibarretxe-Bilbao N, Junque C, Marti MJ, et al. Cerebral basis of visual hallucinations in Parkinson's disease: structural and functional MRI studies. J Neurol Sci, 2011,310(1-2):79-81.
36 Olanow CW, Watts RL, Koller WC. An algorithm(decision tree)for the management of Parkinson's disease(2001): treatment guidelines. Neurology, 2001,56(11 Suppl 5):S1-S88.
37 Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord, 2011,26(Suppl 3):S42-S80.
38 Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol, 2010,67(4):416-421.
39 Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet, 2014,383(9916):533-540.
40 Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol, 2010,67(5):589-595.
41 Zhang G, Zhang Z, Liu L, et al. Impulsive and compulsive behaviors in Parkinson's disease. Front Aging Neurosci, 2014,6:318.
42 Garcia-Ruiz PJ, Martinez CJ, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry, 2014,85(8):840-844.
43 Phu A L, Xu Z, Brakoulias V, et al. Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients. J Clin Neurosci, 2014,21(1):63-66.
44 Cormier F, Muellner J, Corvol J C. Genetics of impulse control disorders in Parkinson's disease. J Neural Transm, 2013,120(4):665-671.
45 Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology, 2013,80(9):792-799.
46 Thomas A, Bonanni L, Gambi F, et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol, 2010,68(3):400-404.
47 Moum SJ, Price CC, Limotai N, et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One, 2012,7(1):e29768.
48 Santangelo G, Barone P, Trojano L, et al. Pathological gambling in Parkinson's disease. A comprehensive review. Parkinsonism Relat Disord, 2013,19(7):645-653.
49 Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology, 2010,75(12):1062-1069.
50 Anang JB, Gagnon JF, Bertrand JA, et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology, 2014,83(14):1253-1260.
51 Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol, 2010,9(12):1200-1213.
52 Gerrits NJ, van der Werf YD, Hofman M, et al. Gray matter differences contribute to variation in cognitive performance in Parkinson's disease. Eur J Neurol, 2014,21(2):245-252.
53 Yong SW, Yoon JK, An YS, et al. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol, 2007,14(12):1357-1362.
54 Adler CH, Caviness JN, Sabbagh MN, et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol, 2010,120(6):827-828.
55 Cappellano G, Carecchio M, Fleetwood T, et al. Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis, 2013,2(2):89-107.
56 Paris A P, Saleta H G, de la Cruz C M M, et al. Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. Mov Disord, 2011,26(7):1251-1258.
57 Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry, 2015,86(2):135-143.
58 Wesnes KA, Aarsland D, Ballard C, et al. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry, 2015,30(1):46-54.